Trials / No Longer Available
No Longer AvailableNCT03906357
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Incyte Corporation · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemigatinib |
Timeline
- First posted
- 2019-04-08
- Last updated
- 2022-04-19
Source: ClinicalTrials.gov record NCT03906357. Inclusion in this directory is not an endorsement.